| Veterinary APIs | Manufacturing and sale of active pharmaceutical ingredients primarily for animal health. | Backward integration, strong regulatory compliance, and established customer relationships. | Primarily B2B serving top animal health companies worldwide. | Highly integrated in-house manufacturing leading to cost advantages. | 227 | 62 | Sales of APIs and intermediates to pharmaceutical companies globally, mostly B2B. | Predominantly direct sales with long-term contracts. | Increasing demand in veterinary sector, expanded capacity, and regulatory approvals. | |
| Human APIs and formulations | APIs and intermediates for human health plus limited finished dosage forms. | Regulatory certifications enable access to controlled markets. | Pharmaceutical companies and healthcare providers. | | 7 | 2 | Direct sales to pharmaceutical firms and some formulations supply. | Direct sales contracts. | Product portfolio expansion and regulatory fililngs. | |
| Geographic Markets | Distribution of pharmaceutical products across India, Asia Pacific, Europe, USA, and Rest of World. | Global regulatory approvals and diversified market presence reduce regional risks. | Global pharmaceutical companies and distributors. | | 368 | 100 | Sales revenue from multiple global markets. | Varies by market but primarily direct sales. | Global demand growth and diversification across regions. | |
